risperdal consta 50mg prášek a rozpouštědlo pro injekční suspenzi s prodlouženým uvolňováním
janssen-cilag s.r.o., praha array - 10707 risperidon - prášek a rozpouštědlo pro injekční suspenzi s prodlouženým uvolňováním - 50mg - risperidon
sporanox 10mg/ml perorální roztok
janssen-cilag s.r.o., praha array - 9219 itrakonazol - perorální roztok - 10mg/ml - itrakonazol
topamax 100mg potahovaná tableta
janssen-cilag s.r.o., praha array - 10722 topiramÁt - potahovaná tableta - 100mg - topiramÁt
topamax 15mg tvrdá tobolka
janssen-cilag s.r.o., praha array - 10722 topiramÁt - tvrdá tobolka - 15mg - topiramÁt
topamax 25mg potahovaná tableta
janssen-cilag s.r.o., praha array - 10722 topiramÁt - potahovaná tableta - 25mg - topiramÁt
topamax 50mg potahovaná tableta
janssen-cilag s.r.o., praha array - 10722 topiramÁt - potahovaná tableta - 50mg - topiramÁt
veletri 0,5mg prášek pro infuzní roztok
janssen-cilag international n.v., beerse array - 5520 sodnÁ sŮl epoprostenolu - prášek pro infuzní roztok - 0,5mg - epoprostenol
veletri 1,5mg prášek pro infuzní roztok
janssen-cilag international n.v., beerse array - 5520 sodnÁ sŮl epoprostenolu - prášek pro infuzní roztok - 1,5mg - epoprostenol
vermox 100mg tableta
janssen-cilag s.r.o., praha array - 1913 mebendazol - tableta - 100mg - mebendazol
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.